When was Nanobiotix founded?

Nanobiotix was founded in 2003 and raised its 1st funding round 7 years after it was founded.

Where is Nanobiotix located?

Nanobiotix is headquartered in Paris, France.

How many employees does Nanobiotix have?

As of Aug 31, 2026, the latest employee count at Nanobiotix is 143.

Is Nanobiotix a funded company?

Nanobiotix is a funded company, having raised a total of $11M across 9 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on May 03, 2010.

When was the latest funding round of Nanobiotix?

Nanobiotix's latest funding was a $***** Post IPO round on Dec 04, 2023, with participation from 1 investor.

Where does Nanobiotix rank among its competitors?

Nanobiotix ranks 11th amongst 300 active competitors, of which 112 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was FoRx Therapeutics, which secured $50M in Dec, 2025.

Who are the top competitors of Nanobiotix?

Nanobiotix's top competitors include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Among them, FoRx Therapeutics secured the most recent funding round in December, 2025.

Nanobiotix - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of nanotherapeutics designed to enhance cancer treatment via radioenhancement. Its lead candidate is designed to increase the dose of radiotherapy absorbed by tumor cells. This is intended to destroy the target tumor and prime the immune response. The company collaborates with institutions to develop therapies for cancer.

Website: nanobiotix.com
Social
Email ID: *****@nanobiotix.com
Phone Number: +33 **********

Key Metrics

Founded Year

2003

Location

Paris, France

Stage

Public

Total Funding

$11M in 9 rounds

Latest Funding Round

Post IPO, Dec 04, 2023, $*****

Investors

European Investment Bank & 11 more

Ranked

11^th among 300 active competitors

Employee Count

143 as on Aug 31, 2026

Similar Companies

Abcellera Biologics & 388 more

Exit Details

Public

View Nanobiotix's full profile

Nanobiotix got listed on Oct 29, 2012.

Click here to take a look at Nanobiotix's IPO in detail

Nanobiotix has raised a total funding of $11M over 9 rounds. Its first funding round was on May 03, 2010. Its latest funding round was a Post IPO round on Dec 04, 2023 for $*****. 1 investor participated in its latest round. Nanobiotix has 12 institutional investors.

Here is the list of recent funding rounds of Nanobiotix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 04, 2023	9866429	Post IPO	1422100	4505718	2389006	6231135
Mar 04, 2019	5004248	Conventional Debt	2755688	7161637	1779869	European Investment Bank
Oct 16, 2018	6328586	Conventional Debt	9489179	6201118	7374568	European Investment Bank

Access funding benchmarks and valuations. Sign up today!

View details of Nanobiotix's funding rounds and investors

Nanobiotix's employee count trend

Nanobiotix has 143 employees as of Aug 26. Here is Nanobiotix's employee count trend over the years:

Uncover Nanobiotix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nanobiotix include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Here is the list of Top 10 competitors of Nanobiotix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
2nd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
3rd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
4th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	67/100
5th	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	63/100
6th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
7th	Cumulus Oncology 2017, Edinburgh (United Kingdom), Seed	Developer of therapies for treating cancers	$19.2M	Eos Advisory, Scottish Investment Bank & 26 others	61/100
8th	Black Diamond Therapeutics 2017, Cambridge (United States), Public	Developing MasterKey therapies to defeat cancer resistance and improve patient lives	$207M	Boxer Capital, RA Capital Management & 19 others	61/100
9th	Boundless Bio 2018, San Diego (United States), Public	Developer of therapeutics for cancer by targeting ecDNA	$252M	RA Capital Management, Bayer & 19 others	61/100
10th	FoRx Therapeutics 2019, Basel (Switzerland), Series A	Developer of compounds for treating cancer	$60.8M	Omega Funds, Novartis Venture Fund & 5 others	60/100
11th	Nanobiotix 2003, Paris (France), Public	Developer of nanotherapeutics designed to enhance cancer treatment via radioenhancement	$11M	European Investment Bank, Masseran Gestion ... & 10 others	60/100